Document Detail


Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients?
MedLine Citation:
PMID:  17593158     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is not surprising that women with inflammatory bowel disease (IBD) have a greater risk of an adverse pregnancy outcome. Although it is ideal to be in remission during conception and pregnancy, women often flare during this critical time. Paradoxically, while pregnant, women often stop the medications that have worked so well to maintain remission due to the fear that these drugs may harm the fetus. Many women with IBD find it especially difficult to continue 6-mercaptopurine (6-MP) and azathioprine (AZA) during pregnancy. There have been a number of studies of IBD and pregnancy but none have successfully separated out the effects of disease activity and drug therapy on pregnancy outcomes. The study by Norgard et al. in this issue of the American Journal of Gastroenterology is the first to combine the power of two national data registries of hospitalizations, outpatient visits, and births with a national prescription database. The authors have detailed information on 900 babies born to mothers with Crohn's disease as well as information on every IBD drug prescribed during pregnancy from 1996 to 2004. The worrisome results here are the greater risk of preterm birth and congenital abnormalities among patients prescribed AZA/6-MP throughout their pregnancies. However, although the authors have accurate information on drug exposure during pregnancy, their measures of disease activity cannot be as accurate due to the nature of this database study. Only a prospective pregnancy registry of IBD patients can adequately differentiate the effects of disease activity and medication use on adverse pregnancy outcomes.
Authors:
Sonia Friedman
Related Documents :
1285888 - The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rh...
8672028 - Repeated successful pregnancies after kidney transplantation in 102 women (report by th...
20231008 - Angiogenic imbalances: the obstetric perspective.
17420668 - Understanding estimated glomerular filtration rate: implications for identifying chroni...
19968838 - Improved prediction of ovulation time may increase pregnancy rates to artificial insemi...
12501868 - Acog committee opinion. safety of lovenox in pregnancy. number 276, october 2002. commi...
Publication Detail:
Type:  Comment; Editorial    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  102     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-26     Completed Date:  2007-08-02     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1414-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Congenital Abnormalities / epidemiology,  etiology
Crohn Disease / drug therapy*
Drug Prescriptions
Female
Glucocorticoids / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use*
Incidence
Infant, Newborn
Pregnancy
Pregnancy Complications*
Pregnancy Outcome
Truth Disclosure*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Glucocorticoids; 0/Immunosuppressive Agents
Comments/Corrections
Comment On:
Am J Gastroenterol. 2000 Nov;95(11):3165-70   [PMID:  11095336 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predicting curriculum and test performance at age 11 years from pupil background, baseline skills an...
Next Document:  Just a spoonful of sugar helps the medicine go down...If only it was that simple! nonadherence in in...